Compare DexCom, Inc. (DXCM) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lufax Holding Ltd — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Lufax Holding Ltd trades at $0.96 (market cap $982.89M). The key difference: DexCom, Inc. is far larger — about 32.4× Lufax Holding Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Lufax Holding Ltd for 13 Days on average.
| DXCM | LU | |
|---|---|---|
Market Cap | $31.86B | $982.89M |
Volume | 3,607,070 | 3,323,384 |
Sector | Health | Financials |
52-Week High | $92.34 | $3.93 |
52-Week Low | $54.84 | $0.95 |
Typical Hold Time | 62 Days | 13 Days |
Enterprise Value | $31.32B | $58.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
LU trades at $0.9814, down 2.83% on the day, with a bearish technical signal from moving averages but a bullish signal from oscillators. The company reported a net loss of $2.10 billion on revenue of $23.11 billion in 2025, with negative profit margins and ROE. A 10:1 reverse stock split was implemented on October 23, 2026, and recent news highlights ongoing restructuring and regulatory challenges in China's consumer lending market.
The outlook remains challenging due to persistent losses and revenue declines, but deep value is suggested by a low P/B of 0.07 and significant analyst buy ratings (69%). Key risks include regulatory tightening and liquidity shocks in China, while potential catalysts include balance sheet strength and operational improvements under parent company Ping An's backing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
